Welcome to our dedicated page for CYBIN SEC filings (Ticker: HELP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc. (HELP) received a Schedule 13D reporting that Chief Growth Officer Paul Glavine, together with PLG Family Trust, beneficially owns 4,407,456 common shares, representing 5.8% of the outstanding common shares. Glavine has sole voting and dispositive power over 4,071,252 shares held directly and shared voting and dispositive power over 230,941 common shares and warrants exercisable for 105,263 common shares held through PLG Family Trust. PLG Family Trust itself reports beneficial ownership of 336,204 common shares, or 0.4% of the class, including shares underlying warrants. The holdings were acquired using personal funds, trust working capital, and employee incentive awards, and are held for investment purposes and as part of issuer employee incentive compensation.
CYBIN INC. (HELP) reports that Chief Growth Officer Paul Glavine purchased 90,000 Common Shares on August 31, 2026 at $11.5853 per share in an open-market or private transaction. After this buy, he holds 4,071,252 Common Shares directly and 230,941 shares indirectly through the PLG Family Trust. No Rule 10b5-1 trading plan is reported, and the filing is made voluntarily, as he is not subject to Section 16 reporting requirements.
CYBIN INC. (symbol HELP) reports the initial beneficial ownership of Chief Growth Officer Paul Glavine as of August 31, 2026. He holds 3,981,252 Common Shares directly and 230,941 Common Shares indirectly through the PLG Family Trust, plus warrants held by that trust exercisable for 105,263 Common Shares.
The report states it is being filed voluntarily and that the reporting person is not otherwise subject to Section 16 reporting requirements. A footnote indicates the reported warrants held via the PLG Family Trust were acquired in 2019.
Cybin Inc. (operating as Helus Pharma) reported that its CEO, Michael Halstead, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York City, with a live webcast on September 11, 2026 at 8:00 a.m. EDT. The event is part of a conference running from September 9-11, 2026 and will be accessible via the Events & Presentations section of Helus Pharma’s investor relations website, with a replay available.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at promoting neuroplasticity to address depression, anxiety and other mental health conditions. Its lead program HLP003 is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. FDA, while HLP004 is in Phase 2 for generalized anxiety disorder. The company also notes an extensive research portfolio of investigational NSAs and operations in Canada, the United States, the United Kingdom and Ireland, and includes extensive forward-looking statement and regulatory cautionary language.
CYBIN INC. (HELP) filed a Form D for a new exempt offering of stock options under Regulation D, claiming the Rule 506(b) safe harbor. The offering covers stock options exercisable at $11.78 per share, expiring on August 19, 2036 and vesting in eight quarterly tranches beginning on August 19, 2026.
The notice states that $0 has been sold to date, with a total remaining amount to be sold of $261,987, described as the maximum potential proceeds from option exercises. No finders’ fees are payable, and the issuer indicates it declines to disclose its revenue range. The securities are in the health care/biotechnology industry group.
CYBIN INC. (HELP) filed a Form D for an exempt offering of equity-based compensation under Rule 506(b) of Regulation D. The offering consists of an aggregate of 1,175,000 restricted share units that vest annually through August 20, 2029. As of the filing, $0 of securities had been sold and no finders' fees were reported. CYBIN is a biotechnology company organized in Ontario, Canada, and this notice covers a new offering with a stated first sale date of August 3, 2026.
CYBIN INC. (HELP) filed a Form D to report an exempt equity compensation offering under Rule 506(b) of Regulation D. The offering consists of an aggregate of 425,000 performance share units (PSUs) that vest annually through August 3, 2029, upon satisfaction of specified conditions. As of this notice, the total amount sold is $0, indicating a new award structure rather than a cash capital raise. No finders' fees are payable, and the company declined to disclose its revenue or asset size. The PSUs are securities to be acquired upon exercise or vesting of rights, intended for executives, directors, or other related persons named in the filing.
CYBIN INC. (symbol HELP), doing business as Helus Pharma, is calling a virtual annual general and special shareholders’ meeting on September 22, 2026. Holders of its 73,060,172 common shares as of August 14, 2026 may attend and vote online.
Shareholders are asked to: receive audited financial statements for the year ended March 31, 2026; appoint Zeifmans LLP as auditor; approve setting the board at eight directors; approve a special resolution to change the corporate name to “Helus Pharma Inc.”; and elect eight director nominees.
The circular details extensive executive compensation and a rolling Equity Incentive Plan that can issue up to 20% of outstanding shares, plus significant RSU and PSU grants to senior management. It reports a total shareholder return of approximately -82% from April 1, 2021 to March 31, 2026 and a net cash position of $157.3 million as of March 31, 2026, supported by financings completed between 2022 and 2026.
Cybin Inc. (HELP) filed a Form 6-K as a foreign private issuer for August 2026. The company states that Exhibit 99.1 to this report is incorporated by reference into its existing short-form base shelf registration statement on Form F-10 (File No. 333-292294), including any amendments or supplements. The report is signed on behalf of Cybin Inc. by Chief Financial Officer Greg Cavers on August 18, 2026. No additional financial or transactional details are provided in this filing itself.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Cybin Inc. Common Shares. They collectively report 3,029,500 Common Shares beneficially owned, including 969,500 shares issuable upon exercise of warrants, representing 4.8% of Cybin’s Common Shares outstanding.
Their stake is based on 61,984,078 Common Shares outstanding as of June 29, 2026. All reported shares are held through investment funds managed by Sirenia, with shared voting and dispositive power and no sole voting or dispositive power for either reporting person.